AptarGroup (NYSE:ATR) Announces Quarterly Earnings Results, Beats Estimates By $0.05 EPS

AptarGroup (NYSE:ATR – Get Free Report) issued its earnings results on Thursday. The industrial products company reported $1.52 EPS for the quarter, topping the consensus estimate of $1.47 by $0.05, Zacks reports. The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $980.76 million. AptarGroup had a net margin of 9.22% and a return on equity of 13.31%.

AptarGroup Stock Performance

Shares of ATR traded up $3.62 during mid-day trading on Thursday, hitting $130.78. 649,713 shares of the company traded hands, compared to its average volume of 491,301. The stock has a market cap of $8.32 billion, a price-to-earnings ratio of 23.65, a P/E/G ratio of 3.92 and a beta of 0.34. AptarGroup has a 1 year low of $103.23 and a 1 year high of $146.91. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.10 and a current ratio of 1.61. The stock has a 50-day moving average price of $125.84 and a two-hundred day moving average price of $126.92.

Insider Activity

In other news, CEO Gael Touya sold 3,740 shares of the firm’s stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $133.76, for a total value of $500,262.40. Following the completion of the sale, the chief executive officer owned 29,102 shares in the company, valued at approximately $3,892,683.52. This trade represents a 11.39% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Stephan B. Tanda sold 9,838 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $136.16, for a total value of $1,339,542.08. Following the sale, the chief executive officer directly owned 238,729 shares of the company’s stock, valued at $32,505,340.64. This represents a 3.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 23,197 shares of company stock valued at $3,134,828. Company insiders own 0.73% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on ATR shares. Raymond James Financial reaffirmed an “outperform” rating and set a $160.00 target price on shares of AptarGroup in a research note on Wednesday, July 15th. Bank of America upgraded shares of AptarGroup from a “neutral” rating to a “buy” rating and set a $173.00 price objective for the company in a report on Tuesday, July 14th. UBS Group initiated coverage on AptarGroup in a research report on Friday, October 9th. They set a “neutral” rating and a $135.00 price objective on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of AptarGroup in a report on Monday, September 21st. Finally, Wells Fargo & Company increased their target price on AptarGroup from $145.00 to $155.00 and gave the stock an “overweight” rating in a research report on Monday, August 3rd. Six analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $164.14.

View Our Latest Stock Analysis on AptarGroup

About AptarGroup

(Get Free Report)

AptarGroup, Inc (NYSE: ATR) develops and manufactures dispensing, sealing and delivery systems for the pharmaceutical, beauty, personal care, food and beverage markets. Its products are designed to control, protect and dispense a wide range of liquids, creams, lotions, fragrances and other formulations.

The company’s offerings include pumps, valves, closures, aerosol systems and other dispensing components, as well as drug-delivery technologies. Through its pharmaceutical business, Aptar supports nasal, pulmonary, ophthalmic, dermal and injectable applications, serving pharmaceutical and biotechnology companies with components and systems used in prescription, over-the-counter and consumer health products.

Aptar serves customers internationally through manufacturing, research and development and commercial operations across North America, Europe, Asia and other global markets.

Read More

Earnings History for AptarGroup (NYSE:ATR)

Receive News & Ratings for AptarGroup Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AptarGroup and related companies with MarketBeat.com's FREE daily email newsletter.